Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 9,743 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the transaction, the insider owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This trade represents a 28.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Vaxcyte Trading Up 0.7%

PCVX traded up $0.32 on Friday, hitting $46.46. 836,943 shares of the company were exchanged, compared to its average volume of 1,226,027. The company has a market cap of $6.08 billion, a price-to-earnings ratio of -9.60 and a beta of 1.34. The firm has a 50-day moving average price of $45.79 and a two-hundred day moving average price of $38.59. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $93.77.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period last year, the business earned ($0.83) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Vaxcyte in the 2nd quarter worth $32,109,000. Westfield Capital Management Co. LP raised its holdings in Vaxcyte by 42.4% during the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock worth $99,770,000 after purchasing an additional 913,761 shares in the last quarter. Deep Track Capital LP lifted its position in Vaxcyte by 39.5% in the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $108,060,000 after purchasing an additional 850,000 shares during the period. Qube Research & Technologies Ltd acquired a new stake in Vaxcyte in the second quarter valued at about $26,318,000. Finally, State Street Corp boosted its holdings in Vaxcyte by 12.1% in the 2nd quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after purchasing an additional 534,552 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price on the stock. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $97.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.